

IONIS-MAPTRx

Cat. No.:	HY-132582
CAS No.:	2857842-32-9
Molecular Weight:	7182
Target:	Tau Protein
Pathway:	Neuronal Signaling
Storage:	-20°C, sealed storage, away from moisture * In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)

IONIS-MAPTRx

SOLVENT & SOLUBILITY

In Vitro	H ₂ O : 100 mg/mL (13.92 mM; Need ultrasonic)				
		Mass			
		Solvent Concentration	1 mg	5 mg	10 mg
	Preparing Stock Solutions	1 mM	0.1392 mL	0.6962 mL	1.3924 mL
		5 mM	0.0278 mL	0.1392 mL	0.2785 mL
10 mM		0.0139 mL	0.0696 mL	0.1392 mL	
Please refer to the solubility information to select the appropriate solvent.					

BIOLOGICAL ACTIVITY

Description	IONIS-MAPTRx (BIIB080) is the first Tau-lowering antisense oligonucleotide (ASO). IONIS-MAPTRx has the potential for the research of Alzheimer Disease ^[1] .
In Vivo	Intrathecal administrations of IONIS-MAPTRx in nonhuman primates showed a mean MAPT mRNA reduction of 77% in frontal cortex and 74% in hippocampus without dose-limiting side effects ^[1] . MCE has not independently confirmed the accuracy of these methods. They are for reference only.

REFERENCES

- [1]. Rationale for and Development of IONIS-MAPTRx, the First Tau-lowering Antisense Oligonucleotide, in Patients with Mild AD
- [2]. DeVos SL, Miller RL, Schoch KM, et al. Tau reduction prevents neuronal loss and reverses pathological tau deposition and seeding in mice with tauopathy. *Sci Transl Med.* 2017;9(374):eaag0481.
- [3]. Methods for reducing tau expression. WO2023004390A1

[4]. Laurence Mignon, et al. Design of the First-in-Human Study of IONIS-MAPTRx, a Tau-lowering Antisense Oligonucleotide, in Patients With Alzheimer Disease (S2.006).
Neurology Apr 2018, 90 (15 Supplement) S2.006.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA